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INTRODUCTION {#s1}
============

Hepatitis E virus (HEV) is a common cause of community acquired viral hepatitis.^[@R1]^ The infection is endemic in many developing countries ^[@R2]^ with a prevalence of as high as 50% .^[@R3]^ In non-endemic countries, the prevalence varies between 1% to 20% .^[@R4]^ This virus like hepatitis A does not lead to chronic hepatitis or carrier state in immunocompetent hosts. A special feature of HEV is its high mortality among pregnant women, which may reach up to 20-25% of cases.^[@R5]^ The infection could also become chronic in immunocompromised hosts specially recipients of solid organ transplantation.^[@R6]^

HEV has been reported worldwide, but it is more common in Central and South-West Asia.^[@R5]^ At least two epidemics of HEV have been reported from Iran in 1990 in Kermanshah province in western border of the country and in 1992 in Chahar Mahal and Bakhtiari province in central Iran.^[@R7]^

Out of these epidemics there are different reports of HEV prevalence in Iran.^[@R8]^ As HEV could cause both acute hepatitis in general population, and chronic disease in immunocompromised hosts, it is of utmost importance to have an estimate of this infection in the whole nation. This is not only of importance for Iran but could also help to better understand the epidemiology of this infection in other transitional societies. This study aimed to determine the seroprevalence of HEV in Iran in a systematic review and meta-analysis.

MATERIALS AND METHODS {#s3}
=====================

Databases: {#s3-1}
----------

We performed a literature search on PubMed, Scopus, Science direct, Google Scholar, Scientific Information Databank (SID), IranMedex, and Magiran till March 2015 for HEV. Studies published in either English or Persian languages were included in the systematic review. The references of all selected published articles from the above databases were also searched to find more relevant studies. The abstract book of national and international conferences with the topic of liver disease, hepatology, hepatitis, and infectious diseases were also searched for HEV.

Search strategy: {#s3-2}
----------------

Search strategy was based both on Medical Education Subject Headings (Mesh) terms as well as free text words and words in the title or abstract of studies. We used the following search strategy "HEV" OR "Hepatitis E Virus" AND "seroepidemiology" OR "Epidemiology" OR "Prevalence" AND "Iran", in Persian or English languages.

Study Selection: {#s3-3}
----------------

The inclusion criteria were: studies that had data indicating the seroprevalence of HEV using standard methods. The exclusion criteria were: studies that did not clearly separate the prevalence of HEV form other viral diseases, studies with unknown sample origins, studies with overlapping time, subjects and place of sample collection, case reports and case series, studies focusing on treatment, studies reporting on HEV among patients with non-Iranian nationality.

Data Extraction: {#s3-4}
----------------

Two investigators (Masoud.Behzadifar and Meysam.Behzadifar) independently applied inclusion criteria and selected studies and extracted the data. Data from the included studies, including the name of the first author, year of publication, location of study, age, sex, type of study, sample size, and number of the infected cases and conflicts were recorded for further analysis.

Assessment of studies: {#s3-5}
----------------------

STROBE questionnaire was used ^[@R9]^ to assess the quality of the studies. All studies were scored by two investigators (Gholamreza.Ghoreishinia, Abouzar.Keshavarzi) separately and mean score was calculated for each study. The studies with score less than 7.5 were considered as poor quality. For 38 articles in this review, the obtained score was 18.11.

Statistical Analysis: {#s3-6}
---------------------

In studies where the SE (standard error) was not reported we calculated it from the prevalence using the following formula:

$$\text{SE=}\sqrt{P(1 - P)/N}\quad(P = prevalence,\, N = sample\, size)$$

Confidence interval (CI) 95% = P±1.96×SE

Studies were estimated with respect to the prevalence with CI and P value. Statistical heterogeneity among the included studies were measured by Cochrane Q statistic and I2.10 Rank of I2 was predefined as a Cochrane Q of 25%=low heterogeneity, 50%=medium heterogeneity, and 75%= high heterogeneity, respectively. P\<0.05 was considered as statistically significant. We considered studies reporting HEV in Iran using random effects model. Meta-regression analysis of the variables of each study such as sample size, and the year of publication, sex, type of study, and the subgroup analyses were done when possible. Publication bias was assessed by Egger's ^[@R11]^ and Begg's ^[@R12]^ tests and graphically depicted by a funnel plot. All data analyses were conducted with STATA software Version 11.0 (Stata Crop LP, College Station, Texas, USA).

RESULTS {#s4}
=======

Based on our search strategy described above 521 articles were initially retrieved. Of them, 148 articles were excluded as duplicate publications. We carefully read the titles and abstracts of the remaining 373 articles and further 170 records were excluded based on the exclusion criteria mentioned above. After reading the full text of the remaining 203 articles, an additional 135 articles were further found to have one of the exclusion criteria. Finally, 38 studies^[@R13]-[@R50]^ were found eligible for final analysis and were used for this meta-analysis. This systematic review and meta-analysis is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines 51 are shown in [figure 1](#F1){ref-type="fig"}.
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Included studies consisted of cross sectional and case control designs. The characteristics of all studies are demonstrated in [table 1](#T1){ref-type="table"}.

###### Characteristics of included studies in the meta-analysis

  ---------------- ---------- ------------ ----------------- ----------------------------- --------- ------------------- ----------------------------
  **Author**       **Year**   **Sample**   **Location**      **Sample population**         **Sex**   **Type of study**   **Age**

  Eini             2015       153          Hamedan           Hemodialysis patients         M/F       Cr-Sec              \>40 - \<60

  Beladi Mousavi   2014       47           Ahvaz             Hemodialysis patients         M/F       Cr-Sec              55.27 ± 8.1

  Rostamzadeh      2013       136          Urmia             Pregnant Women                F         Cr-Sec              25.12 ± 4.91

  Ahmadi           2013       1582         Mashhad           General population            M/F       Cr-Sec              29.06 ± 18.513

  Ehteram          2013       530          Arak              Blood donors                  M/F       Cr-Sec              18-50

  Zekavat          2013       356          Jahrom-Shiraz     Hemodialysis patients         M/F       Cr-Sec              24-80

  Rostamzadeh      2011       91           Urmia             Renal Transplant Recipients   M/F       Cr-Sec              35.4 ± 14.5

  Sepanlou         2010       1423         Tehran-Golestan   General population            M/F       Cr-Sec              37.9±13.4

  Mobaien          2013       93           Zanjan            Hemodialysis patients         M/F       Cr-Sec              57.0 ± 18.5

  Saffar           2009       1102         Sari              General population            M/F       Cr-Sec              2--25

  Taremi           2008       1824         Nahavand          General population            M/F       Cr-Sec              34.7 ±19.5

  Ataei            2009       816          Isfahan           General population            M/F       Cr-Sec              6 - \>50

  Assarehzadegan   2008       400          Khuzestan         Blood donors                  M/F       Cr-Sec              18-60

  Taremi           2007       399          Tabriz            Blood donors                  F         Cr-Sec              31.4±9.8

  Taremi           2005       324          Tabriz            Hemodialysis patients         M/F       Cr-Sec              53.5 ± 15.1

  Ramezani         2013       152          Tehran            Patients HIV                  M/F       Cr-Sec              38.73 ± 0.78

  Mohebbi          2012       551          Tehran            General population            M/F       Cr-Sec              41.28 ±16.96

  Nazer            2012       400          Khorramabad       General population            M/F       Cr-Sec              36

  Tahamtan         2013       150          Gorgan            Hemodialysis patients         M/F       Cr-Sec              \>30 - \<70

  Ghadir           2007       697          Golestan          General population            M/F       Cr-Sec              43±15.1

  Moradi           2010       1200         Gorgan            Pregnant Women                F         Cr-Sec              27±6.3

  khoshbaten       2001       324          Tabriz            Hemodialysis patients         M/F       Cr-Sec              53±15.11

  Gachkar          2005       399          Tabriz            Blood donors                  F         Cr-Sec              40.7±12.4

  shavakhi         2007       200          Tehran            liver cirrhosis               M/F       Ca-Con              ca=43±14.6,cl=44.9±17.5

  Eslamifar        2012       184          Tehran            Patients HIV                  M/F       Ca-Con              38.82±0.8

  Rezazadeh        2006       280          Hamedan           Blood donors                  M/F       Cr-Sec              \>40 - \<40

  Alavi            2007       228          Ahvaz             Drug addiction                F         Cr-Sec              ca=33.24±7.59,cl=31.2±7.59

  Sharif           2013       558          Kashan            Children                      M/F       Cr-Sec              1 to 15

  Noroozi          2012       740          Qom               General population            M/F       Cr-Sec              \>15

  Mohebbi          2012       493          Tehran            General population            M/F       Cr-Sec              40.98±17.10

  Ghorbani         2007       800          Tehran            Military                      M         Cr-Sec              19±1

  Somi             2007       200          Azerbaijan        Blood donors                  M/F       Cr-Sec              48.26±18.19

  Pourahmad        2009       43           Jahrom            Hemodialysis patients         M/F       Cr-Sec              59.3 ± 14.4

  Shamsizadeh      2009       566          Ahvaz             Children                      M/F       Cr-Sec              6 to 15

  Aminiafshar      2004       90           Tehran            Blood donors                  M/F       Cr-Sec              31.8±11

  Keramat          2014       262          Hamedan           Drug addiction                M/F       Cr-Sec              IDUs=35.57 ± 8.13,non\
                                                                                                                         \
                                                                                                                         IDUs=31.57 ± 8.19

  Joulaei          2015       158          Shiraz            Patients with HIV             M/F       Cr-Sec              39.1 ± 8

  Farshadpour      2015       510          Ahvaz             community-based               M/F       Cr-Sec              45.89 ± 14.63
  ---------------- ---------- ------------ ----------------- ----------------------------- --------- ------------------- ----------------------------

M/F: Male -- Female, Cr-Sec: Cross -- Sectional, Ca-Con: Case-Control, IDUs= Injection Drug Users

###### Characteristics of study population and percentage in 38 studies included in meta-analysis of hepatitis E virus prevalence in Iran

  ----------------------------- -------------------- ----------------- --------------------- ------------------- ---------
  **Subgroups**                 **No. of studies**   **Sample size**   **Prevalence %**      **Heterogeneity**   

                                                                       **(95%CI)**           **I** ^2^           ***p***

  Blood donors                  7                    2298              12.3%\                87.0%               0.000
                                                                       \[0.087 to 0.160\]                        

  General population            11                   10138             12.1\                 98.8%               0.000
                                                                       \[0.078 to 0.164\]                        

  Military                      1                    800               11%\                  \-                  \-
                                                                       \[0.004 to 0.019\]                        

  Patients with HIV             3                    494               10.5%\                88.6%               0.000
                                                                       \[0.029 to 0.181\]                        

  Hemodialysis patient          8                    1490              9.5%\                 85.6%               0.000
                                                                       \[0.059 to 0.132\]                        

  Drug addiction                2                    490               9%\                   95.5%               0.000
                                                                       \[-0.030 to 0.211\]                       

  Children                      2                    1124              6%\                   90.9%               0.000
                                                                       \[0.014 to 0.107\]                        

  liver cirrhosis               1                    200               5.5%\                 \-                  \-
                                                                       \[0.023 to 0.087\]                        

  Pregnant women                2                    1336              5.4%\                 56.1%               0.131
                                                                       \[0.029 to 0.079\]                        

  Renal transplant recipients   1                    91                3.8%\                 \-                  \-
                                                                       \[0.213 to 0.403\]                        
  ----------------------------- -------------------- ----------------- --------------------- ------------------- ---------

Seroprevalence of HEV decreased by reduced sample size and later publication year bu t it was not significant. In table 3, a summary of data related to meta-regression is shown.

###### Result of Meta- regression investigating the effect of sample size and year on seroprevalence of hepatitis E virus in Iran

  ------------- ----------------- -------------------- ------- ------- ----------- ------------
                **Coefficient**   **Standard error**   **T**   *p*     **L CI**    **UCI**
  Sample size   -.0000275         .0000329             -0.84   0.409   -.0000942   .0000392
  Year          .005872           .0041553             1.41    0.166   -.0025636   . .0143076
  Cons          -11.68132         8.353102             -1.40   0.171   -28.63902   5.276378
                                                                                   
  ------------- ----------------- -------------------- ------- ------- ----------- ------------

LCI: Lower Confidence Interval UCI: Upper Confidence Interval Cons=Index is calculated in this study, SE (Standard Error)

The total sample size included 18,461 participants from 38 studies. The result of Q Cochran test (chi squared=1194.08, D.F =37, *p*=0.000 and I2=96.9 %.) indicated strong heterogeneity among the 38 studies. According to the random model analysis, the overall seroprevalence of HEV in Iran was estimated 10% (95 % CI=0.09-0.12) with a maximum and minimum value of 46% (95% CI=0.42-0.50), and 0.01% (95 % CI=0.000-0.002), respectively ([figure 2](#F2){ref-type="fig"}).
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In all included studies, individuals were entered randomly. The maximum seroprevalence rate of 46% was reported by Farshadpour from Ahvaz (2015) in southwest border of Iran and Iraq. The minimum seroprevalence rate of 1% was reported by Ghorbani in Tehran and by Saffar in Yazd located in the central desert of Iran in 2010 and 2006, respectively. Seroprevalence rate in both sexes (female-male) was 11% (95% CI=0.09-0.14), the seroprevalence rate in female patients was 8% (95 % CI=0.05-0.10), and the seroprevalence in male patients was 1% (95% CI=0.00-0.02) ([figure 3 A](#F3){ref-type="fig"} ). The seroprevalence rate was 11% (95% CI=0.09-0.13) in cross sectional studies and 8% (95% CI=0.02-0.15) in case control studies ([figure 3 B](#F4){ref-type="fig"}).

###### Fig. 3
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To assess publication bias by a funnel plot, we used Begg's and Egger test. The results of Begg's was *p*=0.068 and Egger tests was *p*=0.000. This finding indicates a significant publication bias ([figure 4](#F5){ref-type="fig"}).
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DISCUSSION {#s5}
==========

Studies in different parts of the world show a wide variation in the seroprevalence of HEV. The present study estimated the overall seroprevalence of HEV in Iran as 10%. There was a wide variation in HEV seroprevalence in the included studies in this meta-analysis. The highest report belonged to Ahvaz, the center of Khozestan province in our border with Iraq. The population in this region travel frequently to Iraq. There are several reports of endemicity of HEV in Iraq even in Baghdad, the capital.^[@R52],[@R53]^ Interestingly although the general trend of the publications shows a lower prevalence in recent years, the situation is reverse in Khozestan and Ahvaz showing an increase in the prevalence from 11.5% in a study in 2008 to 46% in 2015. This corresponds to a period of more mobility along Iran / Iraq border in recent years. The disposal of waste water in Ahvaz also has faced many challenges especially after the recent cycles of drought and flood in the province in contrast to the lowest prevalence reported from Tehran with much better sanitation. The other region with much lower prevalence is Yazd with its surrounding deserts and dry weather.

In our meta-analysis the prevalence of HEV among children and pregnant women was 6% and 5.4% respectively. This is probably because of higher exposure of people with advanced age but as we had limited data we could not confirm the effect of age on seroprevalence.

The prevalence of HEV was not different among patients receiving hemodialysis, intravenous drug users, and HIV infected patients compared to the general population. One should realize that the most common route of HIV infection in Iran is still intravenous drug use, although the trend is moving toward sexual route.^[@R54]^ This indicates that in concordance with other reports, the major route of transmission of HEV is fecal oral rather than parenteral.

It is of interest that in patients with cirrhosis the prevalence was 5.5% and in renal transplant recipients it was 3.8%. As these reports were based on serology and these patients might have exposure to HEV with loss of antibody over time due to malnutrition or immunosuppression, our estimates in these special groups might be incorrect.

This systematic review and meta-analysis has advantage of a relatively large sample size with merging data of good quality studies but it also has several limitations. Although the included studies were from many parts of the country, there were some regions with no data. For instance we could not find any eligible study from two regions with confirmed epidemics of HEV in Iran naming Kermanshah and Chahar Mahal Bakhtiari provinces. The studies analyzed in this systematic review used several different types of serology for HEV from different sources, and their comparability is not known. There was a lack of appropriate data on the age and sex in some of the included studies. Consequently, we were not able to analyze the data by stratifying these variables. Using the information on sex and age, we could better estimate the prevalence of hepatitis E among subgroups in our society. Substantial heterogeneity of 95.7%, according to the I^2^ statistic is another limitation. Of utmost importance is that none of the studies reported the prevalence of HEV among patients suffering from acute hepatitis. Despite these limitations, our study reveals that HEV in Iran is not rare and is not limited to epidemics.

HEV in Iran has an estimated prevalence of 10%. The infection seems to have a decreasing trend overtime, which might be related to improved sanitation and better access to safe water but the pattern is not uniform across the entire country with existence of certain confounders such as mobility along borders especially to countries with high endemicity of HEV. Further prospective studies on incidence of infection, especially in patients suffering from acute hepatitis in non-epidemic conditions are required to obtain better knowledge on the dynamics of this virus in our country.
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